FY2025 Earnings Forecast for EW Issued By Leerink Partnrs

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Equities research analysts at Leerink Partnrs raised their FY2025 earnings estimates for Edwards Lifesciences in a research report issued on Thursday, April 24th. Leerink Partnrs analyst M. Kratky now forecasts that the medical research company will post earnings of $2.48 per share for the year, up from their prior estimate of $2.42. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences' FY2027 earnings at $3.22 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The firm had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the prior year, the firm posted $0.66 EPS. The firm's revenue was up 6.2% compared to the same quarter last year.

EW has been the topic of a number of other reports. Robert W. Baird increased their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Piper Sandler raised shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $73.00 to $80.00 in a report on Thursday, April 24th. Finally, Wolfe Research cut shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $79.45.

Edwards Lifesciences Stock Down 1.4 %

NYSE EW traded down $1.03 during trading hours on Friday, reaching $75.25. 1,400,453 shares of the company traded hands, compared to its average volume of 4,980,719. Edwards Lifesciences has a 12 month low of $58.93 and a 12 month high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $44.24 billion, a PE ratio of 10.80, a PEG ratio of 4.82 and a beta of 1.15. The company has a 50 day moving average of $70.99 and a two-hundred day moving average of $71.20.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Prosperity Consulting Group LLC increased its holdings in shares of Edwards Lifesciences by 3.6% during the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after buying an additional 134 shares in the last quarter. Arlington Trust Co LLC increased its holdings in shares of Edwards Lifesciences by 1.2% in the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock valued at $804,000 after purchasing an additional 135 shares in the last quarter. Abacus Planning Group Inc. raised its position in Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock worth $2,977,000 after purchasing an additional 140 shares during the last quarter. Valeo Financial Advisors LLC lifted its holdings in Edwards Lifesciences by 2.8% during the 1st quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company's stock worth $372,000 after buying an additional 142 shares in the last quarter. Finally, Versant Capital Management Inc boosted its position in Edwards Lifesciences by 9.3% in the 1st quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock valued at $123,000 after buying an additional 145 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $67.96, for a total transaction of $645,620.00. Following the completion of the transaction, the vice president now owns 46,936 shares in the company, valued at approximately $3,189,770.56. This trade represents a 16.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the firm's stock in a transaction dated Wednesday, March 26th. The shares were sold at an average price of $70.87, for a total transaction of $797,287.50. Following the transaction, the chief financial officer now owns 30,387 shares of the company's stock, valued at approximately $2,153,526.69. This trade represents a 27.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 71,853 shares of company stock worth $5,163,062 in the last 90 days. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.